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Objective: Allogeneic hematopoietic stem cell trans-
plantation (Allo-HSCT) is a highly effective post- remission
treatment for patients with AML in ﬁrst complete remission.
The role of post-remission consolidation chemotherapy with
allo-HSCT remains controversial. This study was performed
to evaluate the post-remission chemotherapy efﬁcacy before
Allo-HSCT.
Method: The study included 66 acute leukemia (AML) pa-
tients who received induction regimen containing cytarabine
given for 7 days and idarubicin (7+3) given for 3 days from
April 2008 to July 2013. Thirty -two of patients received only
induction therapy (group A) and 34 patients (group B)
received induction and post-remission chemotherapy con-
taining 5 days cytarabine and 2 days idarubicin (5+2). The
conditioning regimen for transplantation was busulfan and
cyclophosphsmide. Graft-versus-host disease (GvHD) pro-
phylaxis regimen consisted of methotraxate and cyclosporin.
Results: The median follow-up was 20 (21 in group A and
19.5 in group B) months. The median time to neutrophil re-
covery was 12 (range: 9 to 50) and 14 (range: 10 to 27) days
in groups A and B, respectively (p¼0.07). The median time to
platelet recoverywas 15 (9 to 47) days in group A and 16 (9 to
54) days in group B (p¼0.54). Acute GvHD occurred in 18
patients (6 in grade I, 8 in grade II, and 4 in grade III) in group
A and 20 patients (5 grade I, 9 grade II, 6 grade III, and 1 ingrade IV) in group B (56.2% vs. 58.8%; p¼0.833). Eight pa-
tients experienced relapses (7 in group A and 1 in group B).
Twenty-one patients (9 in group A and 12 in group B)
expired. The most common causes of death were GvHD (10),
relapse (5) and infection (4). Two-year leukemia-free sur-
vival (DFS) was 65.9% (SE: 9.5%) and 66.4% (SE: 8.3%) in
groups A and B, respectively (p¼0.547).
Conclusion: The study indicated that there were no differ-
ences in allo-HSCT outcomes between patients with or
without consolidation chemotherapy. More cases and longer
time are required to conﬁrm the preliminary data.216
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Background: Leukemic transformation is seen in approxi-
mately 10-20% of patients with chronic myelomonocytic
leukemia (CMML). We carried out this study to analyze the
clinical features and treatment outcomes in these patients.
Methods: After due IRB approval, 275 patients with WHO
deﬁned CMML seen at the Mayo Clinic from 1997 through
2012 were identiﬁed. All patients underwent bone marrow
(BM) and cytogenetic evaluation at diagnosis and trans-
formation. Patients were evaluated for leukemic trans-
formation and their clinical and pathological information
was retrospectively abstracted.
Results: Of 275 patients with CMML, 42 (15%) had docu-
mented leukemic transformation. The median age at trans-
formation was 68 years (range, 18-87); 21 (50%) were male
and the median follow up was 70 months (range, 37 - 112)
with 34 (79%) deaths recorded at last follow up. At initial
diagnosis 13 patients (31%) had CMML-2. The distribution of
patient across different prognostic models was: Mayo prog-
nostic model- 27 (65%) high risk, 14 (33%) intermediate Risk
and 1 (2%) low risk; Global MD Anderson Score- 11 (26%)
high risk, 11 (26%) intermediate-2 risk, 14 (34%) intermedi-
ate-1 risk and 6 (14%) low risk. Five (12%) patients presented
with elevated white blood counts resulting in leukostasis
(clinical blast crises). Ten of 36 (28%) evaluable patients had
cytogenetic clonal evolution at transformation.
Twenty two (51%) patients with leukemic transformation
received standard induction chemotherapy, 5 (12%) received
hypomethylating agents (HMA) and the remainder were
ineligible for further treatment. Fifteen (68%) patients
treated with induction chemotherapy achieved a ﬁrst com-
plete remission (CR1) in comparison to only one (20%) with a
HMA. The median survival after transformation for patients
achieving CR1 was 28 vs. 2.4 months for the rest of the group
(Fig 1, p<0.001). Seven (32%) patients who underwent in-
duction chemotherapy eventually proceeded with allogeneic
stem cell transplantation (SCT) (4 matched unrelated donor,
2 matched related donor and 1 Cord blood transplant), of
which one (14%) relapsed shortly after SCT; the remainder
are currently alive and disease free. Among patients
achieving a CR1, the median survival for patients undergoing
allogeneic SCT was not reached compared to 25 months for
the remainder (Fig 2, p<0.001).
In a univariable analysis, receiving induction chemo-
therapy (p¼0.016), achieving a CR1 (p<0.001) andundergoing
